MBNL1 and Myotonia: Subcutaneous or intravenous administration of these ASOs, called antagomiR-23b and -218, at a total dose of 12.5 mg/kg in HSALR mice caused an increase in MBNL expression, which was sufficient to improve MBNL-dependent mis-splicing events, muscle histopathology, muscle strength, and myotonia [104,105,106,107].